Conclusion: ChEIs, memantine, and GV-971 all can slow the progression of AD but have different effects on respective assessments. Donepezil and GV-971 were relatively well tolerated.
PubMed 38640313 ↗Memantine
The short answer. People are split on Memantine — 54% of 101 say it helped. It is most often used for mood: 95% of 41 reports say that improved. It is well studied — 236 meta-analyses on PubMed. The most common complaint is dizziness.
From 274 mentions in total — the rest didn't say how it went and aren't counted.
What Memantine does, according to users
Of the people who reported each effect, the share who said it got better.
3 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 236 meta-analyses on PubMed ↗ · 311 randomized trials ↗
Conclusion: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
PubMed 26085043 ↗Conclusion: Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy.Additional information is available at www.asco.org/neurooncology-guidelines.
PubMed 34932393 ↗Conclusion: Antidepressants, particularly those acting as noradrenaline or dopamine enhancers, have evidence of efficacy, but they should be avoided in patients with comorbid bipolar disorder. Finally metadoxine and lithium may be particularly suitable in case of comorbid alcohol misuse or bipolar disorder.
PubMed 26693882 ↗270 human trials on ClinicalTrials.gov test Memantine — 168 completed, 21 recruiting now. See all on ClinicalTrials.gov ↗
- Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients · Dementia
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases · Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain · 2019
- Prophylaxis of Neuropathic Pain by mémantine · Neuropathic Pain · 2013
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
The current US prescription label has no boxed warning.
8 recalls of products named for Memantine. Most recent:
- 2026-04-22 · Class II: Failed Dissolution Specifications record ↗
- 2020-05-20 · Class III: Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing. record ↗
- 2020-02-26 · Class III: Failed Dissolution Specifications: High out of specification result observed at stability studies. record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
13,605 adverse-event reports mention Memantine. Most often reported:
- Fall · 996
- Death · 916
- Drug ineffective · 861
- Off label use · 782
- Confusional state · 739
- Fatigue · 646
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Memantine D — a possible rare cause of liver injury (1–3 published cases). LiverTox entry ↗
NIH has funded 36 research projects with Memantine in the title, $25,339,584 in total (1994–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Memantine ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I feel like I have all the positives of Adderall (focus, motivation, mood increase) without any noticeable downsides. No crash, no anxiety, no cardiac issues.”
“I woke up the next day feeling incredible! I felt light and buoyant...I felt light and buoyant. I had a strong desire to be outside in nature...my memory started to improve, my verbal fluency went up as well.”
“Memantine (7/10): For the first few days, I felt amazing on it. I definitely felt an increased mood and decreased anxiety. Those effects subdued...”
“Memantine 10-30mg. Helps me significantly with general anxiety and hypervigilance from cPTSD. It also just generally improves mood when used sparingly.”
Memantine compared
Other options for mood
Sources
- User reports: 274 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate